Terbinafine in the treatment of dermatophyte toenail onychomycosis: A meta-analysis of efficacy for continuous and intermittent regimens

Journal of the European Academy of Dermatology and Venereology

Volumn 27, Issue 3, 2013, Pages 267-272

  Gupta, A K ^a,b   Paquet, M ^b   Simpson, F ^b   Tavakkol, A ^c,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b MEDIPROBE RESEARCH INC   (Canada)

^c NOVARTIS PHARMA AG   (Switzerland)

^d Topica Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TERBINAFINE;

DERMATOPHYTE; DRUG DOSE REGIMEN; DRUG INTERMITTENT THERAPY; DRUG PULSE THERAPY; HUMAN; META ANALYSIS; PRIORITY JOURNAL; REVIEW; TOENAIL ONYCHOMYCOSIS; TREATMENT OUTCOME;

ANTIFUNGAL AGENTS; HUMANS; NAIL DISEASES; NAPHTHALENES; ONYCHOMYCOSIS; TREATMENT OUTCOME;

EID: 84874118438     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2012.04584.x     Document Type: Review

References (39)

1. Zaias N,. Onychomycosis. Arch Dermatol 1972; 105: 263-274.
2. Andre J, Achten G,. Technics of nail biopsy. Ann Dermatol Venereol 1987; 114: 889-892.
3. Ghannoum MA, Hajjeh RA, Scher R, et al. A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol 2000; 43: 641-648.
4. Elewski BE,. Onychomycosis: pathogenesis, diagnosis, and management. Clin Microbiol Rev 1998; 11: 415-429.
5. Gupta AK,. Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States. J Am Acad Dermatol 2000; 43: S81-S95.
6. Roberts DT,. Prevalence of dermatophyte onychomycosis in the United Kingdom: results of an omnibus survey. Br J Dermatol 1992; 126 (Suppl 39): 23-27.
7. Gupta AK, Jain HC, Lynde CW, et al. Prevalence and epidemiology of unsuspected onychomycosis in patients visiting dermatologists' offices in Ontario, Canada - a multicenter survey of 2001 patients. Int J Dermatol 1997; 36: 783-787.
8. Gupta AK, Scher RK, De Doncker P,. Current management of onychomycosis. An overview. Dermatol Clin 1997; 15: 121-135.
9. Baran R, Hay RJ, Garduno JI,. Review of antifungal therapy, part II: treatment rationale, including specific patient populations. J Dermatolog Treat 2008; 19: 168-175.
10. Denning DW, Evans EG, Kibbler CC, et al. Fungal nail disease: a guide to good practice (report of a Working Group of the British Society for Medical Mycology). Br Med J 1995; 311: 1277-1281.
11. Gupta AK, Ryder JE, Lynch LE, Tavakkol A,. The use of terbinafine in the treatment of onychomycosis in adults and special populations: a review of the evidence. J Drugs Dermatol 2005; 4: 302-308.
12. Elewski BE,. Mechanisms of action of systemic antifungal agents. J Am Acad Dermatol 1993; 28: S28-S34.
13. Lamisil. (terbinafine hydrochloride tablets) Prescribing information. [WWW document]. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, URL http://www.pharma.us.novartis.com/product/pi/pdf/Lamisil-tablets.pdf [accessed on 20 December 2011]
14. Warshaw EM,. Evaluating costs for onychomycosis treatments: a practitioner's perspective. J Am Podiatr Med Assoc 2006; 96: 38-52.
15. Gupta AK, Ryder JE, Johnson AM,. Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis. Br J Dermatol 2004; 150: 537-544.
16. Trivedi NA, Shah PC,. A meta-analysis comparing efficacy of continuous terbinafine with intermittent itraconazole for toenail onychomycosis. Indian J Dermatol 2010; 55: 198-199.
17. Krob AH, Fleischer AB Jr, D'Agostino R Jr, Feldman SR,. Terbinafine is more effective than itraconazole in treating toenail onychomycosis: results from a meta-analysis of randomized controlled trials. J Cutan Med Surg 2003; 7: 306-311.
18. Tosti A, Piraccini BM, Stinchi C, et al. Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. J Am Acad Dermatol 1996; 34: 595-600.
19. Pavlotsky F, Armoni G, Shemer A, Trau H,. Pulsed versus continuous terbinafine dosing in the treatment of dermatophyte onychomycosis. J Dermatolog Treat 2004; 15: 315-320.
20. Warshaw EM, Fett DD, Bloomfield HE, et al. Pulse versus continuous terbinafine for onychomycosis: a randomized, double-blind, controlled trial. J Am Acad Dermatol 2005; 53: 578-584.
21. Sigurgeirsson B, Elewski BE, Rich PA, et al. Intermittent versus continuous terbinafine in the treatment of toenail onychomycosis: a randomized, double-blind comparison. J Dermatolog Treat 2006; 17: 38-44.
22. Gupta AK, Lynch LE, Kogan N, Cooper EA,. The use of an intermittent terbinafine regimen for the treatment of dermatophyte toenail onychomycosis. J Eur Acad Dermatol Venereol 2009; 23: 256-262.
23. Alpsoy E, Yilmaz E, Basaran E,. Intermittent therapy with terbinafine for dermatophyte toe-onychomycosis: a new approach. J Dermatol 1996; 23: 259-262.
24. Warshaw EM, Carver SM, Zielke GR, Ahmed DD,. Intermittent terbinafine for toenail onychomycosis: is it effective? Results of a randomized pilot trial. Arch Dermatol 2001; 137: 1253.
25. Gupta AK,. Ciclopirox topical solution, 8% combined with oral terbinafine to treat onychomycosis: a randomized, evaluator-blinded study. J Drugs Dermatol 2005; 4: 481-485.
26. Schram SE, Warshaw EM,. Costs of pulse versus continuous terbinafine for onychomycosis. J Am Acad Dermatol 2007; 56: 525-527.
27. Warshaw EM, Bowman T, Bodman MA, et al. Satisfaction with onychomycosis treatment. Pulse versus continuous dosing. J Am Podiatr Med Assoc 2003; 93: 373-379.
28. Chang CH, Young-Xu Y, Kurth T, et al. The safety of oral antifungal treatments for superficial dermatophytosis and onychomycosis: a meta-analysis. Am J Med 2007; 120: 791-798.
29. Chin B, Knight SG,. Growth of Trichophyton mentagrophytes and Trichophyton rubrum in increased carbon dioxide tensions. J Gen Microbiol 1957; 16: 642-646.
30. Evans EG,. The rationale for combination therapy. Br J Dermatol 2001; 145 (Suppl 60): 9-13.
31. Santos DA, Barros ME, Hamdan JS,. Establishing a method of inoculum preparation for susceptibility testing of Trichophyton rubrum and Trichophyton mentagrophytes. J Clin Microbiol 2006; 44: 98-101.
32. Barros MEdS, Santos DdA, Hamdan JnS,. In vitro methods for antifungal susceptibility testing of Trichophyton spp. Mycol Res 2006; 110: 1355-1360.
33. Coelho LM, Aquino-Ferreira R, Maffei CuML, Martinez-Rossi NM,. In vitro antifungal drug susceptibilities of dermatophytes microconidia and arthroconidia. J Antimicrob Chemother 2008; 62: 758-761.
34. Biancalana FS, Lyra L, Moretti ML, et al. Standardization of hyphal growth inhibition rate as a means of evaluating Microsporum spp. in vitro susceptibility to terbinafine, griseofulvin, and ciclopiroxolamine. Mycopathologia 2011; 172: 279-285.
35. Biancalana FS, Lyra L, Moretti ML, Schreiber AZ,. Susceptibility testing of terbinafine alone and in combination with amphotericin B, itraconazole, or voriconazole against conidia and hyphae of dematiaceous molds. Diagn Microbiol Infect Dis 2011; 71: 378-385.
36. Yazdanparast SA, Barton RC,. Arthroconidia production in Trichophyton rubrum and a new ex vivo model of onychomycosis. J Med Microbiol 2006; 55: 1577-1581.
37. Rashid A, Scott EM, Richardson MD,. Inhibitory effect of terbinafine on the invasion of nails by Trichophyton mentagrophytes. J Am Acad Dermatol 1995; 33: 718-723.
38. Faergemann J, Zehender H, Millerioux L,. Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once daily for 7 and 14 days. Clin Exp Dermatol 1994; 19: 121-126.
39. Schatz F, Brautigam M, Dobrowolski E, et al. Nail incorporation kinetics of terbinafine in onychomycosis patients. Clin Exp Dermatol 1995; 20: 377-383.